Talsma Bryce, Elam Lindsay Hochman, McGrath Stephanie, Zhou Tianjian, Webb Craig B, Duerr Felix Michael
Department of Clinical Sciences, Colorado State University, Fort Collins, CO, United States.
Department of Statistics, Colorado State University, Fort Collins, CO, United States.
Front Vet Sci. 2024 Sep 25;11:1449343. doi: 10.3389/fvets.2024.1449343. eCollection 2024.
With rapidly growing interest in the use of cannabidiol (CBD) in the management of pain and other conditions, more information is needed on the safety and efficacy of this supplement, particularly its co-administration with commonly used pharmaceuticals such as non-steroidal anti-inflammatory drugs (NSAIDs). This study sought to assess the effect of CBD in dogs with mobility impairments, as well as evaluate the clinical tolerance of CBD used together with NSAIDs.
Forty-two client-owned dogs with diagnosed mobility impairments were enrolled in this prospective, double-blind, crossover, placebo-controlled study. Baseline data were collected for 10-14 days followed by random allocation to either placebo or CBD oil for 45 days with a 30-day washout period in between. CBD was dosed at 5 mg/kg orally every 12 h with masked placebo administered at equal volume. Outcome measures included objective gait analysis, accelerometry, and clinical metrology instruments. CBD plasma levels and serum biochemistry were also collected along with hepatic ultrasound if warranted.
Thirty-eight dogs finished the study with thirty-nine included for at least partial analysis. Compared to baseline, dogs receiving CBD showed evidence of improved outcomes based on blinded veterinary assessments and accelerometer data. Compared to placebo, dogs receiving CBD showed some evidence of improved outcomes on CBPI, CSOM, and blinded veterinary assessments, but not for objective outcome measures. There was evidence of increased ALP when CBD was co-administered with NSAIDs compared to CBD administration alone. Additionally, there was evidence of ALT elevations with CBD and NSAID co-administration, but this elevation did not show evidence of an increase over CBD use alone.
These results suggest a potential therapeutic benefit in the administration of CBD for the management of mobility impairments, but greater ALP elevations were seen when administered with NSAIDs. While the sample size of dogs that received further hepatic work-up for liver enzyme elevations is small, chosen diagnostics varied, and liver biopsies were not performed, there did not appear to be clinically apparent liver damage. Further research is needed to better understand the efficacy of CBD in a larger population of dogs and patient tolerance and safety when administered with NSAIDs or other medications long term.
随着人们对使用大麻二酚（CBD）治疗疼痛和其他病症的兴趣迅速增长，需要更多关于这种补充剂的安全性和有效性的信息，特别是其与常用药物如非甾体抗炎药（NSAIDs）联合使用的情况。本研究旨在评估CBD对行动不便犬只的影响，并评估CBD与NSAIDs联合使用时的临床耐受性。
42只确诊行动不便的客户拥有犬只被纳入这项前瞻性、双盲、交叉、安慰剂对照研究。在10 - 14天内收集基线数据，随后随机分配接受安慰剂或CBD油，为期45天，中间有30天的洗脱期。CBD的剂量为每12小时口服5mg/kg，同时给予等体积的掩蔽安慰剂。结果测量包括客观步态分析、加速度测量和临床计量仪器。如有必要，还收集CBD血浆水平和血清生化指标以及肝脏超声检查结果。
38只犬完成了研究，39只犬至少纳入了部分分析。与基线相比，接受CBD的犬只根据盲法兽医评估和加速度计数据显示出结果改善的证据。与安慰剂相比，接受CBD的犬只在犬类骨关节炎疼痛指数（CBPI）、犬类脊柱骨关节炎测量（CSOM）和盲法兽医评估方面显示出一些结果改善的证据，但客观结果测量方面没有。与单独使用CBD相比，CBD与NSAIDs联合使用时碱性磷酸酶（ALP）有升高的证据。此外，CBD与NSAIDs联合使用时有谷丙转氨酶（ALT）升高的证据，但这种升高并没有显示出比单独使用CBD时有增加的迹象。
这些结果表明，在使用CBD治疗行动不便方面可能有潜在的治疗益处，但与NSAIDs联合使用时ALP升高更明显。虽然因肝酶升高而接受进一步肝脏检查的犬只样本量较小，所选诊断方法各异，且未进行肝脏活检，但似乎没有明显的临床肝脏损伤。需要进一步研究以更好地了解CBD在更大数量犬只中的疗效以及与NSAIDs或其他药物长期联合使用时的患者耐受性和安全性。
